Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option
against COVID-19. Because rapidly emerging virus mutants are becoming the next major …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …

Waves of SARS-CoV-2 infection have resulted from the emergence of viral variants with
neutralizing antibody resistance mutations. Simultaneously, repeated antigen exposure has …

The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …

The emergence of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern threatens the efficacy of currently approved vaccines and authorized …

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …